EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter experience with prostate brachytherapy training



Multicenter experience with prostate brachytherapy training



International Journal of Radiation Oncology Biology Physics 51(3 Supplement 1): 199-200




(PDF same-day service: $19.90)

Accession: 035349846

Download citation: RISBibTeXText

DOI: 10.1016/s0360-3016(01)02187-3



Related references

Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. Urology 63(6): 1128-1131, 2004

Brachytherapy versus brachytherapy plus beam radiation for prostate cancer Morbidity outcomes from two prospective randomized multicenter trials. International Journal of Radiation Oncology Biology Physics 54(2 Supplement): 36, 2002

The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team. BrachyTherapy 9(3): 202-207, 2010

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. Bmc Cancer 10(): 572-572, 2011

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 73(2): 341-346, 2008

Self-assessed sexual function is lower after combination external beam radiotherapy and transperineal permanent prostate brachytherapy compared with prostate brachytherapy alone for clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics 45(3 SUPPL ): 430, 1999

Six-year experience of permanent prostate brachytherapy for clinically localized prostate cancer. Hiroshima Journal of Medical Sciences 60(3): 51-56, 2011

Multicenter analysis of impact of high biologically effective dose (BED) on biochemical failure (Phoenix definition) and survival outcomes in patients with Gleason score 7-10 prostate cancer treated by permanent prostate brachytherapy. International Journal of Radiation Oncology*Biology*Physics 69(3-supp-S): 0-0, 2007

High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. British Journal of Radiology 85 Spec No 1: S18-S27, 2013

Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients An intermediate analysis after ten years experience. International Journal of Radiation Oncology Biology Physics 36(1 SUPPL ): 198, 1996

Systematic Review of Focal Prostate Brachytherapy and the Future Implementation of Image-Guided Prostate HDR Brachytherapy Using MR-Ultrasound Fusion. Prostate Cancer 2016: 4754031-4754031, 2016

Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. RadioTherapy and Oncology 83(1): 3-10, 2007

Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. International Journal of Radiation Oncology, Biology, Physics 69(5): 1472-1477, 2007

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. Journal of Contemporary BrachyTherapy 8(3): 165-172, 2016

Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. Clinical & Translational Oncology 11(7): 470-478, 2009